Login / Signup

A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.

Valeria MerzCamilla ZecchettoFrancesca SimionatoAlessandro CavaliereSimona CasalinoMichele PavaranaSimone GiacopuzziMaria BencivengaAnna TomezzoliRaffaela SantoroVita FedeleSerena ContarelliIrene RossiSerena GiacomazziMartina PasquatoCristiana PiazzolaStefano MilleriGiovanni de ManzoniDavide Melisi
Published in: Therapeutic advances in medical oncology (2020)
2017-004522-14.
Keyphrases
  • phase iii
  • open label
  • phase ii
  • study protocol
  • epidermal growth factor receptor
  • clinical trial
  • metastatic breast cancer
  • placebo controlled
  • double blind